Vanguard Capital Management’s Foghorn Therapeutics FHTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$5.66M Buy
1,586,219
+91,608
+6% +$482K ﹤0.01% 3036
2026
Q2
$7.29M Sell
1,494,611
-478
-0% -$2.12K ﹤0.01% 2974
2026
Q1
$7.15M Buy
+1,495,089
New +$8.21M ﹤0.01% 2906

Other funds holding FHTX

Vanguard Capital Management's FHTX Position: Q3 2026 in Review

Vanguard Capital Management increased its Foghorn Therapeutics (FHTX) stake by 6.1% in Q3 2026, buying an estimated $482K and bringing the position to 1,586,219 shares worth $5.66M. The position accounts for ﹤0.01% of the portfolio, ranked #3036.

Vanguard Capital Management first reported a position in FHTX in Q1 2026 and has held it in 3 quarters since. The position peaked at $7.29M in Q2 2026. 121 funds tracked by Wall St. Rank hold FHTX as of Q3 2026.

  • Vanguard Capital Management held 1,586,219 shares of Foghorn Therapeutics worth $5.66M as of Q3 2026.
  • Vanguard Capital Management bought 91,608 Foghorn Therapeutics shares in Q3 2026, an estimated $482K.
  • Foghorn Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3036 holding.
  • Vanguard Capital Management first reported a position in Foghorn Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Foghorn Therapeutics position peaked at $7.29M in Q2 2026.
  • 121 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.